Workflow to improve patient recruitment for clinical trials within hospital information systems - A case-study

Trials

Volumn 9, Issue , 2008, Pages

  Dugas, Martin ^a   Lange, Matthias ^b   Berdel, Wolfgang E ^b   Müller Tidow, Carsten ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOMATION; CLINICAL RESEARCH; DISEASE ACTIVITY; E-MAIL; GERMANY; HOSPITAL INFORMATION SYSTEM; INFORMATION DISSEMINATION; NURSE; PATIENT ASSESSMENT; PATIENT CARE; PATIENT SELECTION; PHYSICIAN; RESEARCH SUBJECT; TERTIARY HEALTH CARE;

EID: 39849108098     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-9-2     Document Type: Article

References (12)

1. McDonald AM Knight RC Campbell MK Entwistle VA Grant AM Cook JA Elbourne DR Francis D Garcia J Roberts I Snowdon C What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies Trials 2006, 7:9.1475627 16603070 10.1186/1745-6215-7-9
2. National Cancer Institute http://www.cancer.gov/
3. National Institutes of Health - Information on Clinical Trials and Human Research Studies http://www.clinicaltrials.gov/
4. National Cancer Institute - Clinical Trials http://www.cancer.gov/ clinicaltrials
5. Embi PJ Jain A Clark J Bizjack S Hornung R Harris MC Effect of a Clinical Trial Alert System on Physician Participation in Trial Recruitment Arch Intern Med 2005, 165:2272-0. 1343501 16246994 10.1001/ archinte.165.19.2272
6. Weiner DL Butte AJ Hibberd PL Fleisher GR Computerized recruiting for clinical trials in real time Ann Emerg Med 2003, 41(2):242-6. 10.1067/ mem.2003.52 12548275
7. Afrin LB Oates JC Boyd CK Daniels MS Leveraging of Open EMR Architecture for Clinical Trial Accrual AMIA Proceedings 2003, 16-20.
8. Agfa Healthcare http://healthcare.agfa.com
9. Büchner T Hiddemann W Berdel WE Wörmann B Schoch C Fonatsch C Löffler H Haferlach T Ludwig WD Maschmeyer G Staib P Aul C Gruneisen A Lengfelder E Frickhofen N Kern W Serve HL Mesters RM Sauerland MC Heinecke A German AML Cooperative Group 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): A randomized trial of the German AML Cooperative Group J Clin Oncol 2003, 21(24):4496-4504. 10.1200/JCO.2003.02.133 14673036
10. Büchner T Berdel WE Schoch C Haferlach T Serve HL Kienast J Schnittger S Kern W Tchinda J Reichle A Lengfelder E Staib P Ludwig WD Aul C Eimermacher H Balleisen L Sauerland MC Heinecke A Wörmann B Hiddemann Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia J Clin Oncol 2006, 24(16):2480-2489. 10.1200/ JCO.2005.04.5013 16735702
11. Guideline for Good Clinical Practice, ICH Topic E6 http://www.emea.eu/
12. Jaspers MW Knaup P Schmidt D The computerized patient record: Where do we stand? Methods Inf Med 2006, 45(Suppl 1):29-39. 17051292